Lyme Disease Testing Market Size and Industry Outlook
According to Dimension Market Research, the Lyme Disease Testing Market size is expected to reach USD 13.6 billion in 2026 and grow to USD 28.6 billion by 2035, registering a CAGR of 8.6% during 2026–2035. Rising tick-borne disease incidence, increasing awareness of early diagnosis, and advancements in laboratory technologies are supporting this expansion.
The global market covers diagnostic products, laboratory services, and technologies used to detect Borrelia infections. Serological assays, molecular diagnostics, immunoassays, culture-based methods, and emerging T-cell-based tests are contributing to the evolution of Lyme disease diagnosis.
Healthcare providers are increasingly prioritizing accurate testing methods to support timely clinical decisions. Investments in automated laboratory systems, improved diagnostic sensitivity, and point-of-care technologies are also creating new opportunities for diagnostic manufacturers and healthcare laboratories.
What Is the Current Overview of the Lyme Disease Testing Market?
The Lyme Disease Testing Market is experiencing steady expansion as healthcare systems strengthen their ability to identify tick-borne infections. Lyme disease, primarily caused by Borrelia burgdorferi, requires appropriate diagnostic evaluation to support clinical management and reduce complications associated with delayed detection.
Increasing disease surveillance, growing physician awareness, and improvements in infectious disease diagnostics are encouraging broader adoption of laboratory testing. Conventional serological methods continue to support routine diagnosis, while molecular technologies and emerging cellular assays are expanding diagnostic capabilities.
Request Sample PDF of This Report: https://dimensionmarketresearch.com/request-sample/lyme-disease-testing-market/
What Is the Expected Value of the Lyme Disease Testing Market by 2035?
● The global market is valued at USD 13.6 billion in 2026.
● The market is projected to reach USD 28.6 billion by 2035.
● The industry is expected to expand at an 8.6% CAGR.
● North America is forecast to hold a 48.7% share in 2026.
● The US market is estimated at USD 6.0 billion in 2026.
● Europe is projected to reach USD 2.7 billion in 2026.
● Japan is expected to reach USD 816 million in 2026.
● Serological tests are forecast to hold a 63.5% share in 2026.
● Blood and serum samples are expected to account for 72.8% in 2026.
● Immunoassays are projected to capture a 59.6% share in 2026.
What Are the Latest Lyme Disease Testing Market Research Findings?
According to the latest market research, serological testing remains the leading test category, supported by established clinical protocols and broad laboratory availability. Immunoassays dominate the technology landscape, while molecular diagnostics are gaining momentum through improvements in pathogen detection and testing efficiency. Blood and serum samples represent the largest sample category because of their compatibility with conventional diagnostic workflows. Diagnostic laboratories maintain the leading end-user position, supported by specialized infrastructure and high testing volumes. Meanwhile, hospitals are emerging as an important growth area as healthcare providers seek faster diagnostic turnaround times and improved clinical decision-making.
Why Is the Lyme Disease Testing Market Growing?
Increasing exposure to infected ticks, changing environmental conditions, and expanding tick habitats are contributing to rising demand for Lyme disease testing. Greater awareness of early diagnosis is encouraging patients and physicians to pursue appropriate laboratory evaluations. Additionally, healthcare investments in molecular diagnostics, automated immunoassays, and advanced infectious disease testing platforms are improving diagnostic accessibility. Growing research activity and public health surveillance programs further support market expansion.
What Are the Key Growth Drivers of the Lyme Disease Testing Market?
● Increasing incidence of Lyme disease and other tick-borne infections.
● Growing awareness of early disease detection and diagnosis.
● Rising adoption of molecular diagnostic technologies.
● Expansion of automated clinical laboratory infrastructure.
● Increasing government investment in disease surveillance.
● Advancements in immunoassays and diagnostic biomarkers.
● Growing demand for faster and more reliable testing solutions.
Which Region Is Expected to Witness the Fastest Market Growth?
North America is expected to maintain its leadership in the Lyme Disease Testing Market, accounting for approximately 48.7% of global revenue in 2026. The region benefits from established laboratory infrastructure, high disease incidence, strong diagnostic awareness, and continued investment in infectious disease testing technologies.
Asia-Pacific is projected to be the fastest-growing regional market, supported by healthcare modernization, expanding diagnostic laboratory networks, and increasing awareness of vector-borne diseases. Japan, China, South Korea, and Australia are contributing to regional development through investments in infectious disease monitoring and molecular diagnostic capabilities.
Country-Level Market Outlook
● United States: The market is estimated at USD 6.0 billion in 2026, growing at an 8.1% CAGR.
● Europe: The regional market is estimated at USD 2.7 billion in 2026, with an 8.0% CAGR.
● Japan: The market is valued at USD 816 million in 2026, with an 8.4% CAGR.
Which Segment Shows the Highest Growth Potential Within the Lyme Disease Testing Market?
Serological Testing and Molecular Diagnostics
Serological tests are expected to maintain their leading position, accounting for approximately 63.5% of the market in 2026. Their widespread clinical acceptance, established laboratory workflows, and cost-effectiveness support continued adoption. ELISA and Western blot testing remain important components of established diagnostic pathways.
However, molecular testing is anticipated to experience faster growth as laboratories explore PCR and nucleic acid amplification technologies. These methods offer opportunities for targeted pathogen detection and improved diagnostic evaluation in selected clinical settings.
● Serological testing supports established diagnostic protocols.
● Molecular diagnostics offer opportunities for improved detection.
● PCR technologies support advanced laboratory testing capabilities.
Read More About This Market: https://dimensionmarketresearch.com/report/lyme-disease-testing-market/
Immunoassays and Molecular Diagnostic Technologies
Immunoassays are expected to dominate the technology segment with an estimated 59.6% share in 2026. Their affordability, clinical validation, scalability, and compatibility with automated laboratory systems support widespread use. Nevertheless, molecular diagnostics are gaining attention as healthcare facilities seek advanced testing solutions, faster workflows, and improved pathogen identification capabilities.
● Immunoassays remain essential for routine antibody detection.
● Laboratory automation improves testing efficiency.
● Advanced molecular platforms create new innovation opportunities.
Lyme Disease Testing Market Dynamics
What Are the Major Trends Shaping the Market?
Increasing adoption of molecular diagnostics is a significant trend shaping the Lyme Disease Testing Market. Laboratories are integrating PCR-based methods and advanced immunological technologies to strengthen diagnostic workflows. Artificial intelligence is also attracting attention through automated result interpretation, quality monitoring, and laboratory workflow optimization. Research into novel biomarkers, multiplex testing, and point-of-care diagnostic platforms is expanding the range of available testing solutions. These developments are encouraging diagnostic manufacturers to prioritize innovation, operational efficiency, and improved clinical usability.
What Are the Future Growth Opportunities in the Lyme Disease Testing Market?
Point-of-care testing represents an important opportunity, particularly in rural healthcare facilities and locations with limited access to centralized diagnostic laboratories. Portable testing platforms and simplified diagnostic workflows could improve access to timely clinical evaluation. Additional opportunities exist in biomarker discovery, advanced molecular assays, and automated diagnostic systems. Strategic partnerships between diagnostic manufacturers, research institutions, and healthcare organizations may also accelerate product development and commercialization. Expanding public health surveillance and investments in infectious disease preparedness are expected to support future industry opportunities.
What Challenges Are Affecting the Market?
Diagnostic complexity during early infection remains a major challenge for the Lyme Disease Testing Market. Antibodies may not be detectable immediately following infection, potentially resulting in false-negative serological results during early disease stages. Differences in clinical presentation and overlapping symptoms with other conditions can further complicate diagnosis. Additionally, regulatory requirements, clinical validation costs, and the need for specialized laboratory infrastructure may restrict the adoption of emerging technologies. Diagnostic manufacturers must address these limitations while maintaining affordability, reliability, and consistent testing performance.
Who Are the Leading Companies in the Lyme Disease Testing Market?
The competitive landscape includes established diagnostic manufacturers, laboratory technology providers, and specialized infectious disease testing companies. Market participants are focusing on assay development, automated platforms, molecular diagnostics, strategic collaborations, and expanded product portfolios.
● F. Hoffmann-La Roche Ltd.
● Abbott Laboratories
● Siemens Healthineers AG
● Danaher Corporation (Beckman Coulter)
● Thermo Fisher Scientific Inc.
● bioMérieux SA
● Bio-Rad Laboratories, Inc.
● QuidelOrtho Corporation
● DiaSorin S.p.A.
● ZEUS Scientific, Inc.
● Trinity Biotech plc
● Gold Standard Diagnostics (Eurofins Technologies)
● T2 Biosystems, Inc.
● IGeneX Inc.
● Oxford Immunotec Ltd. (PerkinElmer)
● Euroimmun SE (Revvity)
● Viramed Biotech AG
● Creative Diagnostics
● Immunetics, Inc.
● CerTest Biotec S.L.
Get 10% instant discount on report purchase
Related Reports:
● Us Human Papillomavirus Market
● China Polyamino Acid Polymers Market
● Sexually Transmitted Diseases Diagnostics Market
Frequently Asked Questions (FAQs)
1. What is the projected size of the global Lyme Disease Testing Market by 2035?
2. What is the expected CAGR of the Lyme Disease Testing Market during 2026–2035?
3. Which region is expected to dominate the global Lyme Disease Testing Market in 2026?
4. Which region is projected to experience the fastest growth in Lyme disease diagnostics?
5. What are the major factors driving demand for Lyme disease diagnostic testing worldwide?
6. Which test type accounts for the largest share of the Lyme Disease Testing Market?
7. Why are molecular diagnostics gaining popularity in Lyme disease detection?
8. Which sample type is most commonly used for Lyme disease diagnostic testing?
9. Who are the major companies competing in the global Lyme Disease Testing Market?
10. How are artificial intelligence and laboratory automation transforming Lyme disease diagnostics?
About Us
Dimension Market Research (DMR) is a global market intelligence and consulting firm delivering data-driven insights that help organizations make informed strategic decisions. With expertise across 12+ industries and global markets, DMR provides syndicated reports, custom research, competitive analysis, white space analysis, and business strategy consulting.
Our research solutions combine analytical rigor, industry expertise, and forward-looking intelligence to identify opportunities, reduce risks, and support sustainable growth. Trusted by clients across diverse sectors, DMR is committed to delivering accurate, actionable insights that enable businesses to navigate evolving market landscapes with confidence.
Contact Us
Phone USA: +17323699777
Phone India: +919310023843
E-mail: [email protected]
Address USA: 957 Route 33, Suite 12 #308, Hamilton Square, NJ-08690
Address India: D44, Sector 6, Noida 201301, India